Testing effectiveness (Phase 2)Looking for participantsNCT07182721
What this trial is testing
SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment
Who this might be right for
HER2-positive, Unresectable, Locally Advanced or Metastatic Breast CancerSKB264Inetetamab
Fudan University 48